There are several new drugs now being used to treat malignant melanoma. Melanoma, the most serious form of skin cancer, is the sixth most common cancer in the UK – it kills more than 2,000 people in Britain each year.
An international study on 945 people showed that taking both drugs led to tumours shrinking by at least a third in 58% of patients – with the tumours stable or shrinking for an average of 11.5 months.
In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.
This data was published in the New England Journal of Medicine. Click here for link